Get the Stockscreener App
29.32
0.24%
0.07
Alkermes Plc stock is traded at $29.32, with a volume of 897.88K.
It is up +0.24% in the last 24 hours and up +12.38% over the past month.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
See More
Previous Close:
$29.25
Open:
$29.15
24h Volume:
897.88K
Relative Volume:
0.54
Market Cap:
$4.98B
Revenue:
$1.51B
Net Income/Loss:
$333.35M
P/E Ratio:
23.65
EPS:
1.24
Net Cash Flow:
$315.22M
1W Performance:
+5.05%
1M Performance:
+12.38%
6M Performance:
+22.06%
1Y Performance:
+21.06%
1-Day Range:
$28.63
$29.50
1-Week Range:
$27.49
$29.75
52-Week Range:
$22.22
$32.88
Alkermes Plc Stock (ALKS) Company Profile
Name
Alkermes Plc
Sector
Phone
00-353-1-772-8000
Address
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
29.32 | 4.98B | 1.51B | 333.35M | 315.22M | 1.24 |
|
ZTS
Zoetis Inc
|
176.74 | 80.59B | 9.15B | 2.43B | 2.31B | 4.92 |
|
HLN
Haleon Plc Adr
|
9.72 | 44.17B | 14.26B | 1.55B | 0 | 0.3327 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.57 | 42.61B | 30.27B | 1.93B | 3.45B | 0.444 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.57 | 18.77B | 16.77B | -959.00M | 1.37B | -2.00 |
|
VTRS
Viatris Inc
|
13.22 | 15.73B | 15.05B | -883.30M | 1.89B | 1.53 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-24 | Upgrade | Stifel | Hold → Buy |
| Jun-17-24 | Initiated | TD Cowen | Buy |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-20-24 | Downgrade | UBS | Neutral → Sell |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Oct-24-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-17-23 | Initiated | UBS | Neutral |
| Nov-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-14-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-16-22 | Initiated | Piper Sandler | Neutral |
| Apr-22-22 | Resumed | Goldman | Buy |
| Apr-20-22 | Initiated | Goldman | Buy |
| Jan-27-22 | Upgrade | Cantor Fitzgerald | Hold → Overweight |
| Dec-01-21 | Initiated | Citigroup | Neutral |
| Oct-07-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-02-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-15-20 | Upgrade | Mizuho | Neutral → Buy |
| Jul-30-20 | Downgrade | Goldman | Neutral → Sell |
| Feb-14-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-14-20 | Reiterated | H.C. Wainwright | Neutral |
| Feb-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Jan-31-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Sep-05-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jul-15-19 | Upgrade | Goldman | Sell → Neutral |
| May-31-19 | Initiated | H.C. Wainwright | Neutral |
| May-01-19 | Downgrade | Citigroup | Buy → Neutral |
| Dec-19-18 | Downgrade | Goldman | Neutral → Sell |
| Dec-14-18 | Initiated | Wolfe Research | Underperform |
| Dec-13-18 | Downgrade | Credit Suisse | Outperform → Underperform |
| Nov-05-18 | Initiated | Piper Jaffray | Neutral |
| Aug-07-18 | Initiated | Stifel | Hold |
| Jun-21-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jun-06-18 | Initiated | B. Riley FBR, Inc. | Buy |
| May-16-18 | Upgrade | Citigroup | Neutral → Buy |
| May-11-18 | Initiated | BofA/Merrill | Buy |
View All
Alkermes Plc Stock (ALKS) Latest News
Insider Sell: Christian Nichols Sells Shares of Alkermes PLC - GuruFocus.com
Alkermes SVP Nichols sells $151,813 in stock - Investing.com
Alkermes plc (NASDAQ:ALKS) Shares Acquired by Pathstone Holdings LLC - MarketBeat
Natixis Advisors LLC Boosts Stock Position in Alkermes plc (NASDAQ:ALKS) - MarketBeat
Axsome Therapeutics eyes approval after Phase III narcolepsy win - Clinical Trials Arena
Loomis Sayles & Co. L P Raises Position in Alkermes plc (NASDAQ:ALKS) - MarketBeat
Intech Investment Management LLC Buys New Shares in Alkermes plc (NASDAQ:ALKS) - MarketBeat
Alkermes to Participate in Upcoming Investor Conferences - StreetInsider.com
Alkermes to Present at Major Healthcare Conferences: Evercore ISI and Piper Sandler | ALKS Stock News - StockTitan
Alkermes: Products Sales, ALKS 2680 Can Still Drive Long-Term Growth - Seeking Alpha
Eagle Asset Management Inc. Reduces Position in Alkermes plc (NASDAQ:ALKS) - MarketBeat
Victory Capital Management Inc. Grows Position in Alkermes plc (NASDAQ:ALKS) - MarketBeat
Alkermes to Participate in Two Upcoming Investor Conferences - GuruFocus.com
Alkermes plc (NASDAQ:ALKS) Shares Sold by Pacer Advisors Inc. - MarketBeat
Primecap Management Co. CA Trims Stock Holdings in Alkermes plc (NASDAQ:ALKS) - MarketBeat
Are Options Traders Betting on a Big Move in Alkermes (ALKS) Stock? - MSN
(ALKS) Trading Report - Stock Traders Daily
Alkermes (NASDAQ:ALKS) pulls back 6.0% this week, but still delivers shareholders respectable 5.8% CAGR over 5 years - Simply Wall St
Alkermes plc (NASDAQ:ALKS) Stock Position Decreased by Segall Bryant & Hamill LLC - MarketBeat
Substance Abuse Treatment Market Expected to Reach High Growth by 2031: Allergan PLC, Alkermes, Noramco. - openPR
Royce & Associates LP Grows Stock Holdings in Alkermes plc (NASDAQ:ALKS) - MarketBeat
Alkermes plc (NASDAQ:ALKS) Shares Purchased by AMG National Trust Bank - MarketBeat
Alkermes, DaVita, Jabil, Ralph Lauren, among potential M&A candidatesBofA - Seeking Alpha
Brokerages Set Alkermes plc (NASDAQ:ALKS) PT at $35.42 - MarketBeat
Alkermes (NASDAQ:ALKS) Price Target Raised to $40.00 at Mizuho - MarketBeat
Alkermes plc (NASDAQ:ALKS) Shares Sold by Principal Financial Group Inc. - MarketBeat
Alkermes (ALKS) to Present at Major Healthcare Conferences: Stifel and Jefferies London | ALKS Stock News - StockTitan
Trend Tracker for (ALKS) - Stock Traders Daily
Alkermes plc (NASDAQ:ALKS) Shares Purchased by Robeco Institutional Asset Management B.V. - MarketBeat
Van ECK Associates Corp Purchases 29,998 Shares of Alkermes plc (NASDAQ:ALKS) - MarketBeat
Wellington Management Group LLP Adjusts Stake in Alkermes PLC - GuruFocus.com
Narcolepsy Insights from Alkermes Presented at Psych Congress and NEI Congress - Sleep Review
Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences - Chicago Star Media
Alkermes EVP Craig Hopkinson sells $309,168 in stock - Investing.com India
Alkermes EVP Craig Hopkinson sells $309,168 in stock By Investing.com - Investing.com Australia
Insider Sale at Alkermes PLC: EVP R&D, Chief Medical Officer Cra - GuruFocus.com
Alkermes raised to buy by Stifel on increased confidence for ALKS2680 - MSN
Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - GuruFocus.com
Vanguard Group Inc's Recent Transaction in Alkermes PLC Shares - GuruFocus.com
Alkermes (NASDAQ:ALKS) Shares Gap UpHere's What Happened - MarketBeat
Alkermes raised to buy by Stifel on increased confidence for ALKS2680 (NASDAQ:ALKS) - Seeking Alpha
Alkermes PLC (ALKS) Shares Up 5.57% on Nov 5 - GuruFocus.com
Alkermes (NASDAQ:ALKS) Upgraded to Buy at Stifel Nicolaus - MarketBeat
A Glimpse Into The Expert Outlook On Alkermes Through 9 Analysts - Benzinga
Stifel raises Alkermes target to $36, upgrades to buy By Investing.com - Investing.com Australia
Stifel raises Alkermes target to $36, upgrades to buy - Investing.com India
Alkermes plc (NASDAQ:ALKS) Holdings Decreased by DekaBank Deutsche Girozentrale - MarketBeat
(ALKS) Proactive Strategies - Stock Traders Daily
Short Interest in Alkermes plc (NASDAQ:ALKS) Drops By 7.9% - MarketBeat
Alkermes plc (NASDAQ:ALKS) Shares Sold by Allspring Global Investments Holdings LLC - MarketBeat
Alkermes holds steady stock target with neutral rating amid royalty segment dip - Investing.com
Alkermes Plc Stock (ALKS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alkermes Plc Stock (ALKS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer |
Nov 11 '24 |
Sale |
30.08 |
58,996 |
1,774,576 |
83,300 |
0.83%
1.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):